RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
RHYTHM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$88.23+2.06 (+2.39%)
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
RHYTHM PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Product revenue, net | $194.77M | $130.13M | $77.43M | $16.88M | $3.15M | 102.6% | +49.7% |
| License revenue | -$5.01M | $0 | $0 | $6.75M | $0 | -2.6% | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| United States | – | $96.11M | $62.43M | $21.08M | $3.15M | – | – |
| Germany | – | – | $6.08M | $954.00K | – | – | – |
| Other | – | – | $8.93M | $1.61M | – | – | – |
| International | – | $34.02M | $15.00M | $2.56M | – | – | – |
From the segment and revenue-disaggregation notes of Rhythm Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.